Optimized Photoactivatable Lipid Nanoparticles Enable Red Light Triggered Drug Release.
Nisha Chander1, Johannes Morstein2, Jan S Bolten3
1Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.
Small (Weinheim an Der Bergstrasse, Germany)
|April 21, 2021
Summary
Photoactivatable lipid nanoparticles (paLNPs) enable light-triggered drug release for enhanced cancer therapy. These novel nanoparticles show promise for improved drug delivery and reduced side effects, mimicking clinically approved formulations.
Area of Science:
- Biomedical Engineering
- Drug Delivery Systems
- Nanotechnology
Background:
- Lipid nanoparticles (LNPs) are crucial for drug delivery, reducing toxicity and enhancing tumor accumulation.
- A key challenge is the slow drug release from LNPs, limiting therapeutic efficacy.
- Site-specific drug release methods are needed to improve treatment outcomes.
Purpose of the Study:
- To develop photoactivatable lipid nanoparticles (paLNPs) for light-controlled drug release.
- To evaluate the properties and performance of paLNPs compared to conventional LNPs.
- To assess the therapeutic potential of paLNPs for cancer treatment.
Main Methods:
- Incorporation of photoswitchable phosphatidylcholine analogs (AzoPC and redAzoPC) into LNPs to create paLNPs.
- Characterization of paLNP structural integrity, drug loading, and size distribution.
- In vitro and in vivo studies using doxorubicin-loaded paLNPs in cancer cell lines and zebrafish embryos.
Main Results:
- paLNPs exhibited comparable structural integrity, drug loading, and size to conventional LNPs.
- Pulsed light irradiation induced 65-70% doxorubicin release from paLNPs via azobenzene isomerization.
- paLNPs demonstrated light-dependent cytotoxicity in vitro and enhanced drug release in vivo with prolonged circulation.
Conclusions:
- paLNPs offer light-induced drug release, overcoming the limitations of slow release from conventional LNPs.
- These paLNPs closely mimic clinically approved formulations while providing an added layer of control.
- The developed paLNPs represent promising candidates for advanced cancer therapy development.
